The MiMedx Group Inc (MDXG) Given Average Recommendation of “Buy” by Analysts

The MiMedx Group Inc (MDXG) Given Average Recommendation of “Buy” by Analysts

Several research analysts recently issued reports on MDXG shares. Needham & Company LLC reiterated a “buy” rating and issued a $15.00 price target (up from $12.00) on shares of MiMedx Group in a research note on Thursday, April 13th. TheStreet upgraded shares of MiMedx Group from a “c+” rating to a “b” rating in a research note on Thursday, March 16th. First Analysis lowered shares of MiMedx Group from an “equal weight” rating to an “underweight” rating and set a $11.00 price objective for the company. in a research note on Tuesday, May 23rd. Zacks Investment Research upgraded shares of MiMedx Group from a “sell” rating to a “hold” rating in a research note on Tuesday, February 21st. Finally, Piper Jaffray Companies began coverage on shares of MiMedx Group in a research note on Friday, March 3rd. They issued an “overweight” rating and a $10.00 price target for the company.

MiMedx Group Inc (NASDAQ:MDXG) has received a consensus rating of “Buy” from the seven ratings firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $12.00.

Shares of MiMedx Group (NASDAQ:MDXG) opened at 14.64 on Monday. MiMedx Group has a 52-week low of $6.94 and a 52-week high of $15.40. The company has a market cap of $1.55 billion, a PE ratio of 104.57 and a beta of 0.97. The company has a 50 day moving average of $13.31 and a 200-day moving average of $9.94.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings results on Friday, April 28th. The medical equipment provider reported $0.07 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.07. The company had revenue of $72.60 million during the quarter, compared to analyst estimates of $72.60 million. MiMedx Group had a net margin of 8.75% and a return on equity of 18.18%. MiMedx Group’s quarterly revenue was up 36.1% compared to the same quarter last year. During the same period last year, the business earned $0.04 EPS. Analysts forecast that MiMedx Group will post $0.30 EPS for the current fiscal year. In other MiMedx Group news, insider William Charles Taylor sold 26,000 shares of MiMedx Group stock in a transaction that occurred on Thursday, April 27th. The shares were sold at an average price of $11.40, for a total transaction of $296,400.00. Following the transaction, the insider now owns 540,460 shares of the company’s stock, valued at $6,161,244. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 12.30% of the stock is owned by insiders.

Large investors have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP boosted its stake in MiMedx Group by 6.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 51,071 shares of the medical equipment provider’s stock valued at $453,000 after buying an additional 2,872 shares during the last quarter. State Street Corp boosted its position in MiMedx Group by 7.6% in the fourth quarter. State Street Corp now owns 3,046,408 shares of the medical equipment provider’s stock worth $26,992,000 after buying an additional 215,108 shares during the period. Comerica Bank boosted its position in MiMedx Group by 5.5% in the fourth quarter. Comerica Bank now owns 107,442 shares of the medical equipment provider’s stock worth $942,000 after buying an additional 5,568 shares during the period. Cutter & CO Brokerage Inc. purchased a new position in MiMedx Group during the fourth quarter worth $170,000. Finally, Russell Investments Group Ltd. purchased a new position in MiMedx Group during the fourth quarter worth $5,541,000. Hedge funds and other institutional investors own 50.47% of the company’s stock. About MiMedx Group

MiMedx Group, Inc is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company’s Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:MDXG”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”}); Receive News & Ratings for MiMedx Group Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for MiMedx Group Inc and related companies with our FREE daily email newsletter.

MiMedx Group, Inc is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company’s Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:MDXG”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment